Related Experiment Video
Updated: Mar 14, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis
Asako Tagawa1, Tomoko Ogawa1, Syuichi Tetsuka1
1Departments of Neurology, International University of Health and Welfare Hospital, 537-3 Iguchi Nasushiobara City, Tochigi 329-2763, Japan.
Abstract:
We here report a case involving a 38-year-old female with relapsing and remitting multiple sclerosis who developed reactivation of hepatitis C virus (HCV) during administration of fingolimod for 16 months. She had been previously treated for chronic hepatitis C with pegylated interferon and ribavirin, and kept an undetectable HCV-RNA state for more than 4 years before fingolimod starting. Although the increased risk for viral reactivation, for example of herpes zoster virus and varicella-zoster virus, during fingolimod treatment is known, this is, to our knowledge, the first case report of HCV reappearance.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

